Viking Therapeutics (VKTX) announced the completion of patient enrollment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics price target raised to $107 from $106 at Canaccord
- Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target?
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Viking Therapeutics’ VK2735: A Promising Step Forward in Metabolic Disease Treatment Justifying a Buy Rating
- Viking Therapeutics’ VK2735 Trials and Strategic Positioning Drive Buy Rating